Description
Tadarad jelly
Tadarad jelly is presented as a combination product containing tadalafil and dapoxetine. Based on the available evidence, tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction, while dapoxetine is a selective serotonin reuptake inhibitor developed for premature ejaculation. Fixed-dose combination products containing both ingredients are used in some markets, but this specific trade name should be verified against local regulatory information.
Active Ingredient and Medicine Class
Tadalafil belongs to the PDE5 inhibitor class. Dapoxetine belongs to the selective serotonin reuptake inhibitor (SSRI) class and is used on demand for premature ejaculation in approved settings. Together, the ingredients are intended to address erectile dysfunction and premature ejaculation in adult men.
Established Medical Uses
Tadalafil is an established treatment for erectile dysfunction and is also used for certain other approved urologic and pulmonary conditions in some jurisdictions. Dapoxetine is used for premature ejaculation where it is approved. Evidence from clinical studies suggests that using a PDE5 inhibitor together with dapoxetine may help men who have both erectile dysfunction and premature ejaculation, although the exact regulatory status of this fixed combination varies by country and is not confirmed here for this product name.
How It Works
Tadalafil relaxes smooth muscle and increases blood flow by enhancing the nitric oxide-cGMP pathway, which helps support erections in response to sexual stimulation. Dapoxetine increases serotonin activity in the nervous system, which can delay ejaculation and improve ejaculatory control. The combination is designed to act on two different mechanisms involved in male sexual function.
Important Safety Information
Tadalafil should not be used with nitrates because the combination can cause a dangerous drop in blood pressure. Caution is also needed with alpha-blockers, significant heart or blood vessel disease, recent stroke or heart attack, severe liver or kidney problems, and with other medicines that may affect blood pressure or tadalafil metabolism. Dapoxetine has important interaction risks with other serotonergic medicines, monoamine oxidase inhibitors, thioridazine, potent CYP3A4 inhibitors, and some medicines that can increase the risk of fainting or serotonin syndrome. Both ingredients may be unsuitable in people with certain cardiovascular conditions. The product should be used only where the combination is appropriate and permitted by local labeling.
Possible Side Effects
Common adverse effects of tadalafil include headache, flushing, nasal congestion, indigestion, back pain and muscle aches. Important serious reactions can include marked low blood pressure, vision or hearing changes, and priapism. Common adverse effects of dapoxetine include nausea, dizziness, headache, diarrhoea, insomnia and somnolence. Dapoxetine may also cause fainting in some patients and can contribute to serotonin syndrome when combined with interacting medicines.
Scientific Evidence
Clinical and review evidence shows that dapoxetine improves intravaginal ejaculatory latency time and patient-reported control of ejaculation compared with placebo, with common but usually non-serious adverse effects. Reviews of pharmacologic treatments for premature ejaculation also identify tadalafil as one of several agents associated with increased latency time. Studies of combined PDE5 inhibitor plus dapoxetine therapy suggest potential benefit for men with both premature ejaculation and erectile dysfunction, but the overall evidence base is smaller than for the individual ingredients.
Medical Information Notice
This summary is provided for educational purposes only and is based on sources available at the time of review. It does not replace the official patient leaflet, product labeling or assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration — CIALIS (tadalafil) tablets, prescribing information
- Salonia A, et al. — Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review — International Journal of Clinical Practice (2016)
